《異動股》朗生醫藥(00503.HK)急反彈40% 成交創逾一年高
朗生醫藥(00503.HK)繼上日(27日)大成交急挫27.4%後,今早(28日)股價反彈,最高見1.79元,現報1.78元,急升40.2%,成交猛增至737萬股,創逾一年高,涉資1,313萬元。
朗生曾於9月中旬公布,大股東國泰國際醫藥建議以協議安排方式將公司私有化,每股作價1.8元,較停牌前溢價26.76%,料涉資最多2.4億元。生效後,公司將申請撤銷股份於聯交所上市地位。截至9月中旬,要約人及一致行動人士目前共持有公司股本68.23%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.